The exploratory trial result of Fespixon in improving postoperative scar cosmesis has been published by a renowned SCI journal, Aesthetic Surgery Journal.

Published Date:2023-01-11

Original Link:https://www.onenessbio.com/en/news_detail194_5.htm

Statement
No	1	Date of announcement	2023/01/11	Time of announcement	01:54:34
Subject	The exploratory trial result of Fespixon in improving postoperative scar cosmesis has been published by a renowned SCI journal, Aesthetic Surgery Journal.
To which item it meets	paragraph 53			Date of events	2023/01/10
Date of occurrence of the event:2023/01/10 Company name:ONENESS BIOTECH CO., LTD. Relationship to the Company (please enter ”head office” or ”subsidiaries”):head office Reciprocal shareholding ratios:NA Cause of occurrence: The exploratory clinical trial result showed that Fespixon compared with the placebo has significant efficacy in post-operative scar maturation and remodeling. This manuscript has been published by a renowned SCI journal, Aesthetic Surgery Journal on January 10th, 2023. Countermeasures:None Any other matters that need to be specified: (1)Fespixon has superior efficacy in promoting wound healing of diabetic foot ulcers and has been launched after new drug approval by TFDA. Oneness Biotech continues to explore the potential therapeutic effects of other chronic wounds, postoperative scar maturation, radiation dermatitis, etc. (2)A placebo-controlled trial exploring the effect of Fespixon in postoperative scar cosmesis has been reviewed and published in Aesthetic Surgery Journal (Impact Factor: 4.485) that affirms the scientific evidence of Fespixon. The clinical results demonstrate the superior efficacy of Fespixon in improving scar maturation and remodeling. (3)The article is available online in Aesthetic Surgery Journal: https://academic.oup.com/asj/advance-article-abstract/doi/10.1093/asj/sjad005/6979913